EP1100526A2 - UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES - Google Patents

UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES

Info

Publication number
EP1100526A2
EP1100526A2 EP99938340A EP99938340A EP1100526A2 EP 1100526 A2 EP1100526 A2 EP 1100526A2 EP 99938340 A EP99938340 A EP 99938340A EP 99938340 A EP99938340 A EP 99938340A EP 1100526 A2 EP1100526 A2 EP 1100526A2
Authority
EP
European Patent Office
Prior art keywords
arthritis
disease
seq
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99938340A
Other languages
German (de)
English (en)
Inventor
Andreas Martinus Maria Miltenburg
Anna Maria Helena Boots
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Priority to EP99938340A priority Critical patent/EP1100526A2/fr
Publication of EP1100526A2 publication Critical patent/EP1100526A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the primary functional role of the immune system is to protect the individual against invading pathogens bearing foreign, that is non-self, antigens.
  • a mechanism is required to discriminate between foreign antigens and autoantigens derived from the individuals own body. Failure of this process of self-non-self discrimination, that is loss of immunological tolerance to self antigens, may lead to immune reactivity to autoantigens resulting in autoimmune disease, involving tissue damage and loss of organ function.
  • autoimmune diseases are considered to be a major problem in human health care. Some autoimmune diseases may be the result of an immunological process directed at one antigen or antigenic complex whereas in others the autoimmune reaction may involve many types of antigens that may be present in multiple organs.
  • Several lines of evidence have indicated that the immune system is involved in the pathology of autoimmune diseases. First, the chances of individuals to develop an autoimmune disease are closely linked to their genetic backgrounds: genes encoding major histocompatibility complex (MHC) class II molecules that present (auto)antigens to responding T cells which recognize MHC-peptide complexes show a strong genetic linkage to disease susceptibility. Second, cells of the immune system such as monocyte/macrophages and T cells infiltrate target organs.
  • MHC major histocompatibility complex
  • T cells of patients with autoimmune diseases proliferate in vitro in response to potentially involved autoantigens.
  • studies in animal models of autoimmunity have unequivocally demonstrated that cells of the immune system such as monocyte/macrophages and T cells are involved in induction and expression of disease activity.
  • RA rheumatoid arthritis
  • autoimmune disorders such as RA
  • existing therapies for the treatment of autoimmune disorders such as RA, in which the immune system generates an unwanted and undesirable inflammatory response, are inadequate.
  • Treatment has focused on relief of symptoms of autoimmune disease rather that on its cause.
  • Most drugs used in the treatment of autoimmune diseases e.g. steroids and non-steroidal anti-inflammatory compounds, are nonspecific and have significant toxic side effects. This is especially problematic since autoimmune diseases are chronic conditions which require the prolonged administration of drugs.
  • Antigen-specific, nontoxic immunosuppression therapy provides a very attractive alternative for the nonspecific immunosuppression.
  • This antigen-specific therapy involves the treatment of patients with the target autoantigen or with synthetic T cell- reactive peptides derived from the autoantigen. These synthetic peptides correspond to T cell epitopes of the autoantigen and can be used to induce specific T cell tolerance both to themselves and to the autoantigen.
  • synthetic T cell- reactive peptides correspond to T cell epitopes of the autoantigen and can be used to induce specific T cell tolerance both to themselves and to the autoantigen.
  • Desensitization or immunological tolerance of the immune system is based on the long-observed phenomenon that animals which have been fed or have inhaled an antigen or epitope are less capable of developing a systemic immune response towards said antigen or epitope when said antigen or epitope is introduced via a systemic route.
  • the human cartilage glycoprotein-39 (HC gp-39) was previously identified as a target autoantigen in RA (Verheijden GFM et al, 1997, Arthritis Rheum., 40, 1115).
  • the autoantigenic nature was demonstrated by selective recognition of DR4 (DRB 1*0401) binding peptides by peripheral blood T cells from RA patients.
  • HC gp-39 as the inducing protein, in Balb/c mice a chronic, relapsing model of autoimmune-arthritis was developed. Following sensitization with a single, systemic injection with a low dose ( ⁇ g range) of HC gp-39 in incomplete Freunds adjuvant (IF A), clinical arthritis developed first in the fore paws. At a later stage, a chronic, second phase of arthritis occurred in the hind paws which waxes and wanes with broad peaks of activity and remained present for at least 250 days. Histological evaluation of hind paws showed marked infiltrates predominantly around the ankle joint. Safranin O staining revealed depletion of proteoglycans indicating degradation of cartilage.
  • IF A incomplete Freunds adjuvant
  • HC gp-39 The model was shown to be useful in the investigation of tolerance induction with HC gp-39 as a novel, specific therapy for RA.
  • nasal application of ⁇ g amounts of HC gp-39 several days prior to induction prevented the onset of HC gp-39 induced arthritis.
  • the mechanism behind this is thought to be T-cell mediated since a DTH response to HC gp- 39 was completely abrogated.
  • Therapeutic use of HC gp-39 was tested by tolerance induction after the first phase of arthritis had occurred.
  • the data indicate that nasal inhalation of HC gp-39 leads to prevention of a broad peak of arthritis activity in the hind paws.
  • HC gp-39 can, in a highly effective manner, be used to induce antigen-specific immunological tolerance (WO 96/13517).
  • an antigen-driven, nontoxic form of immunomodulation therapy could be utilized without knowledge of the antigen(s) that are involved as a target in the (auto)immune response.
  • Such an antigen-driven therapy would involve the generation of antigen-specific modulator cells with the use of an antigen that is expected to be released or produced during the autoimmune process as a result of inflammation or tissue damage.
  • the locally produced autoantigen could then activate or reactivate modulator cells induced with such an antigen.
  • HC gp-39 is being expressed under numerous inflammatory (auto)immune conditions including RA, osteoarthritis (OA), alcohol-induced liver fibrosis, inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE).
  • HA osteoarthritis
  • IBD inflammatory bowel disease
  • SLE systemic lupus erythematosus
  • HC gp-39 is expected to be expressed in those immune conditions in which monocyte to macrophage maturation occurs (Krause SW et al, 1996, J. Leukoc. Biol. , 60, 540) indicating that potentially in all inflammatory autoimmune diseases HC gp-39 can be found.
  • expression of HC gp-39 may not be the direct cause of disease, but the result of localized inflammation.
  • HC gp-39 can effectively modulate disease activity irrespective of the antigen(s) that are involved as a target in the (auto)immune response.
  • the mere presence of HC gp-39 at a site of inflammation or in lymph nodes draining such a site for instance as the result of production during the process of monocyte to macrophage maturation, can result in the activation of modulatory T-cells induced with the use of HC gp-39, and therefore result in downmodulation of disease activity.
  • HC gp-39 does not downmodulate collagen induced arthritis when tested in a scheme designed to prevent the induction of this disease (application on days -15, -10 and -5).
  • HC gp-39 is not effective in downmodulation of arthritis activity when using a pretreatment protocol.
  • HC gp-39 is highly effective in treatment of the autoimmune condition induced with CII when given on days 20, 25 and 30 following arthritis induction. Therefore, when HC gp-39 was given in a therapeutic application schedule that is highly relevant to the clinical situation in which patients present themselves to the doctor with ongoing autoimmune disease, arthritis activity was strongly inhibited. This inhibition of arthritis activity as a result of application of HC gp-39 was much stronger than the effect seen with the antigen used in the induction of disease, collagen type II.
  • HC gp-39 can be used to modulate lymphocytes that are reactive to antigens other than HC gp-39 but are present in the same tissue as HC gp-39.
  • autoimmune disorders can be treated by bystander suppression.
  • the cells to be modulated are hematopoietic cells.
  • the protein in order to function as a tolerogen the protein must fulfill at least two conditions i.e. it must possess an immune modulating capacity and it must be expressed locally or in lymph nodes draining a local site.
  • the present invention provides a method to treat patients suffering from inflammatory autoimmune diseases irrespective of the antigen involved as a target in the immune response, by administration of a pharmaceutical preparation comprising HC gp- 39.
  • a pharmaceutical preparation comprising HC gp- 39.
  • Such patients may suffer from diseases like Graves' diseases, primary glomerulonephritis, osteoarthritis, juvenile arthritis, Sj ⁇ gren's syndrome, myasthenia gravis, rheumatoid arthritis, Addison's disease, primary biliary sclerosis, uveitis, systemic lupus erythematosis, inflammatory bowel disease, multiple sclerosis or diabetes.
  • the polypeptide according to the present invention therefore can be used in the preparation of a pharmaceutical to induce tolerance in patients suffering from these diseases.
  • HC gp-39 or fragments thereof can thus be used for the manufacture of a pharmaceutical preparation for modulation of the reactivity of lymphocytes.
  • lymphocytes may be reactive to antigens other than HC gp-39. They are, however, present in the same tissue as HC gp-39. As a result inflammatory diseases are prevented.
  • HC gp-39 Treatment of autoimmune disorders with HC gp-39 makes use of the fact that bystander suppression is induced to unrelated but co-localized antigens.
  • the regulatory cells secrete in an antigen specific fashion pleiotropic proteins such as cytokines which can downmodulate the immune response.
  • a treatment can be combined with the the administration of other medicaments such as DMARDs (Disease Modifying Anti-Rheumatic Drugs e.g. sulfasalazine, anti-malarials (chloroquine, hydroxychloroquine) mjectable or oral gold, methotrexate, D-penicillamine, azathioprine, cyclosporine, mycophenolate), NSAIDs (non steroidal anti inflammatory drugs), corticosteroids or other drugs knowns to influence the course of the disease in patients suffering from inflammatory diseases.
  • DMARDs Disease Modifying Anti-Rheumatic Drugs e.g. sulfasalazine, anti-malarials (chloroquine, hydroxychloroquine) mjectable or oral gold, methotrexate, D-penicillamine, azathioprine, cyclosporine, mycophenolate
  • NSAIDs non steroidal anti
  • fragments of the tolerogen having the relevant antigenic parts will be sufficient in downregulation of the immune response. Such fragments can be identified by the same assay as described in examples 1 and 2.
  • fragment refers to any sequence of amino acids that is part of the polypeptide defined above, having common elements of origin, structure and mechanism of action that are within the scope of the present invention and which are functionally equivalent to the whole antigen.
  • functional equivalent means a compound having variations of HC gp-39 or fragments thereof while still maintaining functional i.e. immunological or tolerogenizing characteristics of the sequence of HC gp-39 or the epitope fragments.
  • HC gp-39 and the peptides can also be prepared with the aid of recombinant DNA techniques.
  • a nucleic acid sequence which codes for HC gp-39 or a peptide according to the invention or a multimer of said peptide is inserted into an expression vector.
  • Suitable expression vectors are, amongst others, plasmids, cosmids, viruses and YAC's (Yeast Artificial Chromosomes) which comprise the necessary control regions for replication and expression.
  • the expression vector can be brought to expression in a host cell. Suitable host cells are, for instance, bacteria, yeast cells and mammalian cells. Such techniques are well known in the art (Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989).
  • the peptides may be stabilised by C- and/or N- terminal modifications, which will decrease exopeptidase catalysed hydrolysis.
  • N-terminal amide introduction e.g. peptide- NH 2
  • combinations of acylation and amide introduction e.g. Ac-peptide-NH 2
  • D-amino acids instead of L-amino acids
  • modifications are: introduction of D-amino acids instead of L-amino acids, modified amino acids, cyclisation within the peptide, introduction of modified peptide bonds, e.g. reduced peptide bonds ⁇ [CH 2 NH] and e.g. peptoids (N-alkylated glycine derivatives) (Adang et al, Reel. Trav. Chim. Pays-Bas, 113:63-78, 1994 and Simon et al, Proc. Natl. Acad. Sci. USA, 82:9367-9371 , 1992).
  • modified peptide bonds e.g. reduced peptide bonds ⁇ [CH 2 NH]
  • peptoids N-alkylated glycine derivatives
  • HC gp-39 and/or peptides comprising a subsequence of HC gp-39 can be effective in modulation of the immune system.
  • patients in which the tissue is under attack of autoresponsive T cells can be treated with a pharmaceutical composition comprising HC gp-39, or one or more peptides according to the invention and a pharmaceutical acceptable carrier in order to generate T cells in these patients that exert e.g. bystander suppression in such a way that the inflammatory response is diminished.
  • Very suitable peptides to be used in a pharmaceutical composition according to the invention are the peptides comprising an amino acid sequence given in SEQ ID NO: 1 (FGRSFTLAS), SEQ ID NO:2 (FTLASSETG), SEQ ID NO:3 (YDDQESVKS), SEQ ID NO:4 (FSKIASNTQ), SEQ ID NO:5 (PTFGRSFTLASSE, SEQ ID NO:6 (RSFTLASSETGVG), SEQ ID NO:7 (VGYDDQESVKSKV) and SEQ ID NO:8 (SQRFSKIASNTQSR ) of WO 96/13517.
  • Suitable peptides according to the invention are the peptides comprising the SEQ ID NO:
  • ID NOs 1 -8 flanked by sequences up to a total length of 55 amino acids. More preferably the peptides have a length of 25 amino acids. Even more preferably the amino acid sequence of the peptides is identical to the sequence of SEQ ID NO 1-8.
  • Proteins related to HC gp-39 can similarly be used to develop an autoimmune response. Therefore, it is to be expected that these proteins can also be used for subsequent tolerization.
  • Suitable proteins to be used as an alternative for HC gp-39 in a pharmaceutical composition acccording to the invention are for example pig heparine- binding 38kDa protein, bovine 39 kDa whey protein, human YKL-39 protein, murine breast regressing 39kDa protein (brp39), human oviduct-specific glycoprotein, murine oviduct-specific glycoprotein, hamster oviduct-specific glycoprotein, bovine oviduct- specific glycoprotein, human chitotriosidase precursor protein and murine secretory protein YM-1 precursor.
  • DNA (expression)vectors comprising DNA which encodes for HC gp-39 or one or more of the peptides or proteins according to the invention.
  • the DNA (expression)vector can provide by expression a level of the recombinant HC gp-39 protein or fragments thereof according to the invention which is similar to the level which would be achieved by direct administration of a pharmaceutical composition comprising the HC gp-39 protein or peptides.
  • Tolerance can be attained by administering high or low doses of the tolerogen or peptides according to the invention.
  • the amount of tolerogen or peptide will depend on the route of administration, the time of administration, the age of the patient as well as general health conditions and diet.
  • a dosage of 0.01 to 10000 ⁇ g of peptide or protein per kg body weight, preferably 0.05 to 2000 ⁇ g, more preferably 0.1 to 100 ⁇ g of peptide or protein can be used.
  • compositions according to the invention may comprise one or more adjuvants. Suitable adjuvants include, amongst others, aluminium hydroxide, aluminium phosphate, amphigen, tocophenols, monophosphenyl lipid A, muramyl dipeptide and saponins such as Quill A. The amount of adjuvant depends on the nature of the adjuvant itself.
  • composition according to the invention may comprise one or more stabilizers such as, for example, carbohydrates including sorbitol, mannitol, starch, sucrosedextrin and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates.
  • stabilizers such as, for example, carbohydrates including sorbitol, mannitol, starch, sucrosedextrin and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates.
  • Suitable administration routes are intramuscular injections, subcutaneous injections, intravenous injections or intraperitoneal injections, oral and intranasal administration. Oral and intranasal administration are preferred administration routes.
  • modulator cells specific for the antigen could be generated by applying the antigen via the mucosae, for instance the nasal mucosae. Mucosal administration of antigens has been shown to induce immunological tolerance to such antigens.
  • the present invention demonstrates that HC gp-39 can be used to downmodulate autoimmune disease induced with a non-related antigen, thereby supporting the concept that HC gp-39 induced modulator cells can influence autoimmune processes.
  • Figure 1 Effect of nasal application of 30 ⁇ g HC gp-39 on onset and progression of collagen type II induced arthritis in DBA/1 mice.
  • a Effects on a clinical arthritis score in groups of mice
  • b Effects on a clinical arthritis score in individual mice
  • c Inhibition of histo logical alterations as evidenced by infiltrate score
  • d Inhibition of histological alterations as evidenced by photograph of knee joint
  • f Inhibition of radiological damage as evidenced by photographs of ankle joints
  • Example 1 Modulation of collagen-induced arthritis by nasal administration of 30 ⁇ g of HC gp-39
  • Bovine collagen type II was isolated from articular cartilage of knee joints obtained from 1-2 year old calves (Miller EJ, Rhodes RK. In: Colowick SP, Kaplan NO, eds. Methods in Enzymology, Vol 82. New York: Academic Press, 1982:33-65). Collagen was resolved in 0.05M HAc (5 mg/ml) and stored at -70°C.
  • HC gp-39 was isolated from the supernatant of transfected CHO cells. HC gp-39 was purified from the culture supernatant by heparin affinity chromatography followed by superdex 75 chromatography. Purity was checked by SDS-PAGE. The control protein ovalbumin was from Sigma, St. Louis, USA.
  • CFA complete Freund's adjuvant
  • redness and/or swelling score 0: no changes; score 0.5: significant changes; score 1.0: moderate changes; score 1.5: marked changes; score 2.0: severe arthritis accompanied by maximal swelling and redness and later on ankylosis. A further refinement of this score (0.25 increments in the scoring system) has been implemented.
  • Knee joints were evaluated for the presence of histopathological abnormalities. Joints were removed in toto and fixed for 4 days in 4% formalin. After decalcification in 5% formic acid the specimens were processed for paraffin embedding. Tissue sections (7 ⁇ m) were stained with haematoxylin and eosin (HE) in order to detect inflammatory changes or with Safranin O to detect proteoglycan depletion indicative of cartilage breakdown. Histopathological changes were scored according to the following parameters. Infiltration of cells, on a scale of 0 to 3, was assessed based on the amount of inflammatory cells in the synovial cavity and the synovial tissues.
  • Proteoglycan depletion was determined using Safranin O staining, and loss of proteoglycans was scored on a scale of 0 to 3, ranging from fully stained cartilage to destained cartilage or complete loss of articular cartilage.
  • a further score for the progressive loss of articular cartilage is based on cartilage destruction. This destruction was graded on a scale of 0 to 3, ranging from the appearance of dead chondrocytes (empty lacunae) to complete loss of articular cartilage. Histopathological changes in the knee joints were scored in the patella/femur region on five semi-serial sections of the joint. For the ankle joint, the calcanius region was scored.
  • Radiography was performed on hind paws of individual mice at the end of the experiment (day 34). Radiographs were scored with the use of a stereomicroscope under low magnification. A score of 0 to 5 was given to each paw according to the following guidelines: score 0: no changes; score 1 : minor changes; score 2: moderate changes; score 3 : marked changes; score 4: severe changes; score 5: complete destruction reflecting the severe arthritis that was externally visible in a number of animals.
  • mice immunized with collagen type II developed collagen-induced arthritis as planned and expected.
  • Mice treated with the antigen used to induce disease, that is collagen type II showed a trend towards milder disease activity in the earlier phase of the treatment.
  • Mice treated with HC gp-39 were strongly inhibited in their expression of clinical disease activity (Figure 1A). Inhibition of clinical severity of arthritis was first detectable at day 25 of the experiment and lasted until day 34, at the end of the experiment. Only four of the eleven animals treated with HC gp-39 developed an arthritis that was moderate or severe, seven of the eleven mice were more or less protected (Figure IB). Mice treated with ovalbumin or buffer showed clinical arthritis that was comparable with the clinical arthritis seen in control mice ( Figures 1 A and IB).
  • HC gp-39 not only modifies the clinical pattern of disease expression but also prevents ongoing histologically and radiographically detectable alterations that reflect inflammatory and erosive processes that lead to joint destruction and loss of function. Thus, treatment with HC gp-39 actually alters the course of the disease.
  • Bovine collagen type II was isolated from articular cartilage of knee joints obtained from 1-2 year old calves (Miller EJ, Rhodes RK. In: Colo wick SP, Kaplan NO, eds. Methods in Enzymology, Vol 82. New York: Academic Press, 1982:33-65). Collagen was resolved in 0.05M HAc (5 mg/ml) and stored at -70°C.
  • HC gp-39 was isolated from the supernatant of transfected CHO cells. HC gp-39 was purified from the culture supernatant by heparin affinity chromatography followed by superdex 75 chromatography. Purity was checked by SDS-PAGE. The control protein ovalbumin was from Sigma, St. Louis, USA.
  • mice immunized with collagen type II developed collagen-induced arthritis as planned and expected.
  • Mice treated with the antigen used to induce disease, that is collagen type II again showed a trend towards milder disease activity in the earlier phase of the treatment.
  • mice treated with 30 ⁇ g of HC gp-39 were strongly inhibited in their expression of clinical disease activity (Figure 2).
  • Mice that had been treated with 3 or 10 ⁇ g of HC gp-39 also showed inhibition in their expression of clinical disease, although to a lesser extent.
  • Inhibition of clinical severity of arthritis is further detailed by data of hind paws of individual mice experiencing arthritis on evaluation days 23, 25 and 30, again demonstrating clinical effectivity of treatment with HC gp-39, most effectively at the 30 ⁇ g/animal dose.
  • Example 3 HC gp-39 responses in RA patients
  • RA American Rheumatism Association
  • ARA American Rheumatism Association
  • HC gp-39 was purified from culture supernatant by affinity chromatography followed by superdex 75 chromatography. Purity was checked on SDS-PAGE.
  • Candida albicans was obtained from Hal allergenen lab.
  • PBMC Peripheral blood mononuclear cells
  • PBMC obtained from patients with RA proliferated to HC gp-39.
  • Candida albicans was used as a positive control antigen.
  • Six out of ten patients could be classified as being a HC gp-39 responder (SI > 10); four out of ten patients did not respond to HC gp-39 (SI ⁇ 10) (Table 1).
  • Both responders (R) and non- responders (NR) were found in various stages of the disease, either having active or non- active disease at the time of blood sampling.
  • RA patients can be classified into individuals responding to HC gp-39 and individuals not responding to HC gp-39 with the use of a routine proliferation assay.
  • Table 1 HC gp-39 reactivity in RA patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation de la glycoprotéine-39 de cartilage humain (HC gp-39) pour prévenir des maladies inflammatoires. Plus spécifiquement, on peut utiliser la HC gp-39 ou des fragments de celle-ci pour moduler la réactivité des lymphocytes lesquels réagissent aux antigènes autres que HC gp-39 mais sont présents dans les mêmes tissus que ceux où est exprimée HC gp-39.
EP99938340A 1998-07-23 1999-07-19 UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES Withdrawn EP1100526A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99938340A EP1100526A2 (fr) 1998-07-23 1999-07-19 UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98202471 1998-07-23
EP98202471 1998-07-23
PCT/EP1999/005331 WO2000004917A2 (fr) 1998-07-23 1999-07-19 UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES
EP99938340A EP1100526A2 (fr) 1998-07-23 1999-07-19 UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES

Publications (1)

Publication Number Publication Date
EP1100526A2 true EP1100526A2 (fr) 2001-05-23

Family

ID=8233962

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99938340A Withdrawn EP1100526A2 (fr) 1998-07-23 1999-07-19 UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES

Country Status (4)

Country Link
EP (1) EP1100526A2 (fr)
JP (1) JP2002521344A (fr)
AU (1) AU5287599A (fr)
WO (1) WO2000004917A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454342A1 (fr) 2001-07-24 2003-02-06 Yale University Procedes, compositions et necessaires relatifs a des molecules chitinases et de type chitinase ainsi qu'a des maladies inflammatoires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
EP0805206A3 (fr) * 1996-05-03 1999-09-15 Smithkline Beecham Corporation Glycoproteine humaine de cartilage
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0004917A2 *

Also Published As

Publication number Publication date
JP2002521344A (ja) 2002-07-16
WO2000004917A3 (fr) 2000-07-20
WO2000004917A2 (fr) 2000-02-03
WO2000004917A9 (fr) 2000-08-24
AU5287599A (en) 2000-02-14

Similar Documents

Publication Publication Date Title
AU720695B2 (en) Bystander suppression of autoimmune diseases
Lehmann et al. Determinant spreading and the dynamics of the autoimmune T-cell repertoire
US5843449A (en) Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
Dick et al. Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens
WO2003026691A2 (fr) Procede
AU2002341266A1 (en) Use of HMGB1 for the activation of dendritic cells
US10363306B2 (en) Cytokines and neuroantigens for treatment of immune disorders
WO1996012737A9 (fr) Compositions et traitement pour la sclerose en plaques
AU4278296A (en) Compositions and treatment for multiple sclerosis
Miller et al. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
Joosten et al. Induction of tolerance with intranasal administration of human cartilage gp‐39 in DBA/1 mice: Amelioration of clinical, histologic, and radiologic signs of type II collagen–induced arthritis
US20050013824A1 (en) Alpha B crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
AU783170B2 (en) Use of MIA in immunotherapy
EP1100526A2 (fr) UTILISATION DE gp-39 DE CARTILAGE HUMAIN DANS DES MALADIES IMMUNES
US6964766B1 (en) Peptides for use in immunotherapy of autoimmune diseases
WO2002072133A1 (fr) Proprietes immunomodulatrices de bip
Benichou et al. The Secrets of Crypticity and its Relationship to Medical Problems: Autoimmune Disease, Transplantation and Cancer
US20040115217A1 (en) Bystander suppression of autoimmune diseases
Stein Suppression of EAE in the Lewis Rat by Treatment with Neuroantigen-containing Liposomes
MXPA01000789A (en) Novel peptides for use in immunotherapy of autoimmune diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20010720

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020131